State Street Corp V Tv Therapeutics Inc. Transaction History

State Street Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 15, 2022	SELL	$0.65 - $38.8 $46,410 - $2.77 Million	-71,400 Reduced 34.64%	134,745 $131,000
Q2 2022 Aug 15, 2022	BUY	$0.39 - $0.84 $58,588 - $126,191	150,228 Added 268.66%	206,145 $155,000
Q1 2022 May 16, 2022	SELL	$0.51 - $1.0 $188 - $370	-370 Reduced 0.66%	55,917 $40,000
Q4 2021 Feb 14, 2022	SELL	$0.95 - $1.69 $5,130 - $9,126	-5,400 Reduced 8.75%	56,287 $56,000
Q3 2021 Nov 15, 2021	SELL	$1.53 - $2.22 $44,064 - $63,936	-28,800 Reduced 31.83%	61,687 $94,000
Q2 2021 Aug 16, 2021	SELL	$2.27 - $3.44 $427,393 - $647,679	-188,279 Reduced 67.54%	90,487 $206,000
Q1 2021 May 17, 2021	BUY	$1.97 - $2.89 $201,064 - $294,962	102,063 Added 57.76%	278,766 $786,000
Q4 2020 Feb 16, 2021	BUY	$1.49 - $3.1 $1,415 - $2,945	950 Added 0.54%	176,703 $329,000
Q3 2020 Nov 10, 2020	SELL	$1.7 - $2.98 $1,111 - $1,948	-654 Reduced 0.37%	175,753 $311,000
Q2 2020 Aug 14, 2020	BUY	$1.74 - $3.19 $306,948 - $562,738	176,407 New	176,407 $397,000

243K

Ticker VTVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,483,600
Market Cap $1.33B
Description
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetran...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.